The 2025–2028 MedSpa Deal Outlook: Insights From Leading M&A Advisors
Key Takeaways
- The medspa M&A market is entering its strongest consolidation cycle from 2025–2028, driven by demand growth, technology adoption, and private equity expansion.
- Valuations are expected to rise for high-performing, systemized medspas with recurring revenue and strong provider infrastructure.
- Investors are shifting toward scalable, multi-location platforms rather than single-location acquisitions.
- Regulatory complexity and market saturation in some metros will shape buyer strategies over the next four years.
- Medspa owners who invest in financial readiness, team stability, and operational standardization will command the highest exit multiples.
Introduction
To understand where the market is headed, we first need to look at the emerging forces that will shape medspa transactions over the next four years.
The medspa industry is entering one of its most active deal cycles in history. Between 2025 and 2028, leading M&A advisors expect rapid consolidation, rising valuations, and a significant shift in who the dominant buyers will be. This momentum is not occurring in isolation—it is being fueled by a combination of macroeconomic stability, booming consumer demand for non-invasive aesthetic services, and the maturing of medspa operators who are now ready for multi-location expansion.
The sector has grown far beyond its early boutique stage. Medspas today operate sophisticated service lines, leverage AI-driven aesthetic technology, and generate recurring monthly revenue—making them increasingly attractive to private equity-backed platforms. Reports project the global medspa market to grow aggressively throughout the next decade, as shown by recent global medical spa market size and forecast data. For owners, this means the next few years offer an unprecedented opportunity to capture higher valuations, especially for those who prepare early and position their businesses as scalable, systemized, and financially transparent.
Why the Market Is Shifting Faster Than Expected
The medspa space is evolving at a pace that has exceeded analysts’ previous estimates. A few years ago, many assumed consolidation would remain slow because medspas were viewed as small, founder-dependent, localized operations. However, several forces have rapidly accelerated the maturity of the industry, pushing it into the spotlight for institutional investors.
One of the most significant drivers is consumer behavior. Demand for non-surgical treatments—such as injectables, laser procedures, and regenerative skincare—continues to surge, outpacing many traditional elective healthcare services. This surge, coupled with a growing acceptance of aesthetics among younger demographics, is pushing predictable monthly demand higher, which buyers value highly.
At the same time, the entry of AI-powered skin analysis, automated patient follow-up systems, and advanced devices has lifted the sophistication level of medspas. This creates the type of operational consistency private equity platforms look for. As technology reduces dependency on individual providers, medspas begin to resemble scalable consumer-health businesses rather than independent wellness boutiques. This transformation is one reason the deal landscape is shifting much faster than anticipated.
The Key Forces Driving Consolidation Through 2028
These forces create the foundation for the H3 insights that explain exactly how and why consolidation is accelerating.
Consolidation in the medspa sector is not merely a trend—it’s an inevitability. Over the next four years, mergers and acquisitions will reshape the landscape as buyers push aggressively to acquire high-performing practices and build large regional or national networks. The push toward consolidation is rooted in market fragmentation: thousands of independently owned medspas are competing for the same consumer base, yet most operate with minimal standardization. This fragmentation makes it easy for well-capitalized groups to enter the market and scale.
Investors are also motivated by the recurring revenue models that many modern medspas now implement. Memberships, subscription skincare programs, and treatment packages reduce revenue volatility—something highly attractive during due diligence. Meanwhile, clinical innovation is boosting profitability, especially in areas such as regenerative aesthetics and energy-based therapies. These dynamics are creating a perfect storm: more buyer demand, better operating models, and increased seller readiness. For medspa owners, this means the window for premium valuations will remain strong through 2028, but competition among practices may intensify.
How Private Equity Is Reshaping the MedSpa Sector
Private equity’s interest in medspas has moved far beyond exploratory. As of 2025, PE-backed platforms are aggressively building multi-location networks, often acquiring 10–30 practices at a time. Their strategy is long-term: consolidate, centralize operations, standardize service quality, and rapidly expand market share.
These firms see medspas as resilient, cash-flow-positive, and structurally aligned with long-term demand trends. Non-invasive aesthetics outperform traditional cosmetic surgery in terms of growth rate, frequency of repeat visits, and accessibility to younger consumers. This gives PE investors confidence that returns will remain strong even during periods of economic uncertainty.
PE platforms are also reshaping competition by offering medspa owners structured exit packages—often including earn-outs, partial equity rollovers, and leadership roles within a larger network. This creates strong incentives for entrepreneurs who want liquidity without completely stepping away from the brand they built. As a result, private equity’s involvement is not only accelerating consolidation but fundamentally redefining how medspas view growth, succession, and long-term exit planning.
Market Growth Drivers Fueling the Surge in MedSpa Acquisitions
Before diving into the detailed sub-drivers, this section outlines the economic, demographic, and technological forces powering buyer interest.
The medspa industry continues to outperform many other segments of elective healthcare, drawing investor attention for multiple reasons. First, consumer demand for minimally invasive procedures has reached record levels, driven by shifts in lifestyle, the normalization of aesthetic treatments, and strong purchasing power in younger demographics. Second, medspas benefit from diversified service lines, enabling them to generate revenue across injectables, laser therapies, facials, regenerative procedures, and more—creating strong cross-sell potential.
Technology has also become a groundbreaking growth driver…accelerating and shaping investor appetite according to these global aesthetics market growth insights. AI-powered skin diagnostics, automated treatment planning, improved energy-based devices, and virtual consultation platforms are enabling consistent patient outcomes while reducing reliance on clinical staff. This technological edge increases scalability, making medspas even more attractive targets for acquisition. Together, these forces form the backbone of the medspa M&A boom, with demand expected to rise even further through 2028 as innovation accelerates and consumer behavior continues to evolve.
Non-Invasive Aesthetics Demand and Consumer Behavior Shifts
Consumer preferences have dramatically shifted toward non-invasive, low-downtime procedures. Millennials and Gen Z have become core medspa consumers, adopting aesthetics earlier and visiting more frequently than previous generations. This shift toward preventive and enhancement-based treatments increases lifetime customer value and stabilizes revenue flows.
With social media driving awareness and visibility, aesthetics is no longer a luxury—it’s a mainstream component of personal wellness and self-presentation. This has produced consistent treatment cycles, making medspa demand less seasonal and more predictable. Investors recognize the strength of this consumer trend, especially as younger patients are creating long-term treatment habits that will extend for decades. This behavioral shift significantly impacts valuation models because predictable, repeatable demand equals more favorable acquisition terms.
Valuation Trends 2025–2028: What Today’s Buyers Are Paying For
To understand why valuation premiums are rising, we now break down the core components buyers analyze before making an offer, leading naturally into the deeper valuation drivers in the H3 sections below.
MedSpa valuations between 2025 and 2028 are expected to remain strong, with well-run practices commanding higher multiples than at any previous point in the industry’s history. Buyers are increasingly willing to pay premiums for medspas that demonstrate predictable cash flow, diversified service lines, and strong brand authority in their local markets. As the industry matures, investors are becoming more selective—they are not simply buying revenue; they are buying infrastructure, scalability potential, and operational sophistication. This means medspas with clean financial records, standardized processes, and strong clinical governance are positioned to outperform competitors in valuation negotiations.
A major factor influencing valuations is the shift toward recurring revenue models. Memberships, prepaid treatment packages, and subscription skincare programs create consistency that investors love. The more predictable a medspa’s demand cycle is, the higher its valuation ceiling becomes. Additionally, geographic desirability plays a role. Medspas located in high-income, high-growth metropolitan areas or affluent suburban markets often command stronger multiples because the local consumer base supports long-term revenue expansion.
Finally, the introduction of advanced aesthetic technology is raising the bar. Buyers look closely at utilization rates for devices, ROI per treatment room, and provider productivity metrics. Practices that successfully integrate AI tools, automated follow-ups, and high-tech diagnostics often see stronger deal interest. These elements set the stage for the deeper valuation criteria discussed in the following sections.
Updated EBITDA Multiples and What Influences Them Most
EBITDA multiples for medspas are projected to remain competitive through 2028, particularly for practices that are part of high-demand markets or exhibit strong scalability indicators. Historically, medspas could expect multiples in the range of 4–7x EBITDA, but premium operators with multi-location potential may achieve 8–10x or higher depending on buyer appetite and financial structure. These shifts show that the market is maturing and that value is increasingly tied to long-term growth potential rather than short-term profitability alone.
Key factors that influence these multiples include revenue concentration, patient retention rates, and the diversity of treatment offerings. Medspas that rely too heavily on injectables or a single provider may experience downward valuation pressure. In contrast, businesses with balanced, diversified revenue streams create more predictable returns and therefore attract higher bids. The presence of strong managerial infrastructure also plays a crucial role—buyers pay more for practices that can operate independently from their founders.
Additionally, membership programs significantly influence multiples. Investors are willing to pay premiums when 20–40% of monthly revenue comes from recurring subscriptions because this reduces financial volatility. Lastly, EBITDA quality matters. Clean books, prepared year-over-year comparisons, and clear reporting of owner add-backs can increase multiples by proving that earnings are solid and sustainable. These valuation principles lead into the next element: operational red flags that can hinder a medspa’s exit potential.
Who’s Buying? The Investors Dominating MedSpa Deals Through 2028
To explore the investors shaping the future of medspa consolidation, we now transition into an examination of the specific buyer groups driving acquisition demand.
Between 2025 and 2028, the medspa buyer pool will diversify dramatically. Historically, most buyers were individual entrepreneurs or small local groups, but the current landscape has evolved into a sophisticated mix of private equity firms, strategic healthcare investors, and consumer-health companies expanding into aesthetics. This shift signals the industry’s transition from boutique wellness to a scalable, data-driven segment of healthcare services. As more investors recognize the recurring revenue potential of medspas, competition for top-performing practices has intensified.
Private equity remains the most dominant force. Many PE groups have launched aesthetics platforms or expanded existing healthcare portfolios to include medspas. Their focus is on acquiring multi-location practices or building regionally dominant networks through add-ons. Strategic buyers—especially dermatology groups, plastic surgery networks, and MSOs—are also becoming key players, seeking synergies between aesthetics and medical specialties.
Another emerging trend is the rise of lifestyle and consumer brands entering the aesthetic market. Wellness companies, cosmetics brands, and even retail health groups are exploring acquisitions. Their approach often centers on brand extension and consumer experience. This broadening buyer landscape gives sellers more options, more leverage, and greater opportunities to negotiate favorable deal terms, which we explore further in the sub-sections ahead.
Private Equity Roll-Ups and Multi-Location Platform Buyers
Private equity–backed roll-ups are expected to remain the dominant acquisition strategy through 2028. These firms aim to consolidate highly fragmented markets by bringing top-performing medspas under one operational umbrella. Their strategy is clear: acquire, standardize, scale, and expand into new geographic markets. For medspa owners, this represents an opportunity to join a larger platform, gain infrastructure support, and potentially retain equity that grows after the sale.
Platform buyers are particularly focused on medspas with strong operational foundations. This includes documented treatment protocols, consistent marketing performance, stable patient flow, and a management team capable of supporting additional growth. PE firms typically prefer multi-location operations or single-location medspas with immediate expansion potential. Practices with a proven ability to replicate success across locations carry immense appeal.
Valuation structures in PE roll-ups often include earn-outs, seller financing, or equity rollovers that reward owners for future growth. For many sellers, this creates a path to double-dip—getting paid now and again later when the platform resells or recapitalizes. Through 2028, these buyers will lead the charge in shaping the national medspa landscape, creating a competitive environment that raises value-enhancing opportunities for sellers.
Deal Activity Forecast 2025–2028: What M&A Advisors Expect
This forecast sets the stage for the deeper breakdown of market indicators in the H3 sections that follow, helping sellers anticipate upcoming shifts.
According to leading M&A advisors, medspa deal activity will remain strong from 2025 through 2028 due to a unique alignment of market conditions. Demand for aesthetic treatments continues to climb, and buyer capital remains readily available, making medspas one of the most attractive sectors in healthcare acquisitions. Additionally, many founders who started medspas during the post-2018 boom are now approaching the natural exit window, increasing supply in the market.
Advisors expect 2025–2026 to be particularly active years for acquisitions, especially as interest rates stabilize and private equity funds accelerate their deployment schedules. Even if rates fluctuate, the consumer-driven nature of medspas makes them resilient assets during macroeconomic shifts. Buyers will continue to pursue platform acquisitions, but add-on deals will dominate the landscape as established networks seek to strengthen regional footprints.
By 2027–2028, the market may become more competitive for sellers as consolidation reduces the number of high-performing independent operators. However, valuations will likely remain elevated due to strong demand and the long-term viability of aesthetics as a consumer-health category. Sellers who prepare early will be best positioned to capitalize on this cycle before consolidation peaks.
Why the Next Two Years Will Be the Most Active for Sellers
2025 and 2026 are expected to be the most seller-friendly years of the entire 2025–2028 window. First, many private equity firms have dry powder they need to deploy, and medspas offer high margins, predictable growth, and strong consumer demand—making them ideal targets. Second, the stabilization of the broader economy has increased buyer confidence. With inflation cooling and financing environments improving, buyers can model long-term returns more accurately.
Another major factor is demographic timing. Many medspa owners who launched businesses between 2014 and 2019 are now approaching 8–12 years of ownership—a common exit horizon. They are ready to either cash out or join a larger platform to scale further. This naturally increases deal flow at a time when buyers are aggressively competing for quality practices.
Additionally, early consolidators want to secure market position before competition intensifies. Platforms that act now will have first access to the strongest operators, beating out late entrants. For sellers, this means more offers, stronger negotiations, and a larger opportunity to leverage competitive bidding to maximize valuation. This momentum sets the stage for the exit-readiness strategies discussed in the upcoming sections.
The Top Value Drivers MedSpa Sellers Must Strengthen Before Going to Market
Now that we’ve covered market conditions, valuations, and buyer expectations, we can dive deeper into the specific operational and financial drivers that directly influence a medspa’s sale price.
In the 2025–2028 deal cycle, the medspas that command the highest valuations are those that demonstrate strong operational infrastructure, predictable financial performance, and a replicable growth model. Buyers are no longer impressed by high revenue alone; they want a business that can scale, withstand market changes, and deliver consistent clinical outcomes. This means the sellers who want premium multiples must focus on fortifying the core elements buyers evaluate during due diligence.
Among the strongest value drivers are provider productivity, treatment utilization rates, patient retention, and membership adoption. Practices with high monthly recurring revenue appear less risky to investors and typically sell at higher EBITDA multiples. Additionally, buyers closely evaluate team stability—particularly the presence of multiple injectors rather than dependency on the owner. Consistent branding, digital presence, and reputation management also strongly influence perceived value.
Financial transparency is equally important. Clean books, organized KPIs, proper add-back documentation, and accurate forecasting help buyers feel confident in the practice’s performance. Medspas with strong compliance protocols, documented SOPs, and reliable patient-tracking systems also appear more sophisticated—making them more attractive to institutional buyers. These fundamentals lead naturally to the next point: what separates high-value medspas from average ones.
Provider Productivity, Utilization Rates, and Service Mix Optimization
Provider productivity is one of the most powerful value drivers in medspa M&A. Buyers want practices where injectors, aestheticians, and medical directors operate at high efficiency, consistently meeting or exceeding revenue-per-provider benchmarks. A medspa that generates strong revenue evenly across its team is far more valuable than one dependent on a single superstar injector. Balanced productivity reduces operational risk and signals that the practice can continue performing after ownership transitions.
Utilization rates are equally critical. Buyers analyze factors such as treatment room uptime, device ROI, and scheduling efficiency. Underutilized devices or idle treatment rooms indicate poor management and cut into valuation potential. In contrast, medspas that show strong utilization of energy-based devices—lasers, RF microneedling, body contouring platforms—demonstrate strong demand and operational discipline.
Service mix optimization is another powerful driver. Practices that rely too heavily on injectables may appear vulnerable to pricing pressure or staffing issues. Buyers prefer a diversified offering that includes skincare, energy-based treatments, and regenerative services to protect revenue stability. When medspas show balanced, high-margin service lines, they attract more competitive offers. These operational strengths connect directly to the next major variable: compliance and risk mitigation.
Read more: How to Sell Your Healthcare Company in a Market That’s Constantly Changing
Why Some MedSpas Command Premium Valuations—and Others Don’t
The difference in valuations becomes clearer when we drill down into the underlying strengths and weaknesses explored in the H3 subsections below.
Despite strong industry demand, not all medspas receive premium offers. In fact, many practices fall short during due diligence because buyers identify inconsistencies in operations, financials, or compliance. Buyers are looking for businesses that feel polished, organized, and scalable—not chaotic or overly dependent on the owner. A medspa that appears disorganized may still generate strong revenue, but it will often be discounted because buyers fear the business will struggle after transition.
Premium-valued medspas almost always share a common set of traits: high retention rates, professionally branded marketing, strong leadership teams, consistent clinical protocols, and transparent financial reporting. They maintain strict patient safety standards and follow appropriate supervisory requirements for their state. Their digital presence also reflects a strong brand identity—from reviews and SEO to social media engagement. All these factors contribute to perceived stability and growth potential.
Conversely, medspas with inconsistent documentation, unclear expenses, high staff turnover, or unregulated delegation of medical tasks frequently spark concerns for buyers. Regulatory risks can significantly devalue a deal. Pricing inconsistencies, poorly tracked memberships, and low device utilization also harm valuation. These distinctions form a natural pathway to our next breakdown of red flags buyers watch closely.
Red Flags That Reduce MedSpa Valuations During Due Diligence
Due diligence is where deals are won or lost. Even high-revenue medspas can experience valuation reductions—or lose buyers entirely—if major red flags appear. One of the biggest issues is poor financial documentation. Inaccurate books, missing bank reconciliations, unverified add-backs, cash-based inconsistencies, or undocumented expenses create immediate mistrust. Buyers assume that if the financials are unclear, the business will require significant cleanup work post-acquisition.
Team instability is another red flag. If key injectors are contractors rather than employees, or if turnover is frequent, buyers fear revenue loss after ownership change. Employment agreements, non-competes, and retention structures all become critical during negotiations. Inconsistent patient outcomes or poor online reviews can also raise concerns about clinical standards and liability exposure.
Compliance issues—such as unclear supervisory structure, improper delegation, non-compliant advertising claims, or expired device certifications—are among the most severe red flags. Investors carrying institutional capital demand clean compliance. Operational disorganization, lack of SOPs, or missing training protocols also lower valuation. Once these risks are identified, buyers almost always adjust terms or walk away, which reinforces the need for sellers to prepare early.
What MedSpa Owners Should Do Now to Maximize Their Exit Price
With valuation drivers and risk factors now defined, we turn to the practical steps sellers can begin implementing immediately, leading into the tactical H3 sections below.
Preparing for a medspa sale requires strategy, timing, and disciplined operational improvement. The most successful sellers are those who begin preparing 12–24 months before going to market. This preparation window allows owners to optimize financial performance, stabilize their teams, and resolve compliance or operational issues long before buyers review the business. It also gives sellers time to strengthen the narrative behind the practice—highlighting what makes it unique, scalable, and superior to competitors.
Owners should begin by auditing their financials. Clean books, accurate P&Ls, and clear add-back schedules can increase the final valuation significantly. Next, leaders should evaluate staffing. Are injectors stable? Do employment agreements exist? Is the business relying too heavily on the owner? Reducing owner dependency, even gradually, can raise valuation.
Operational optimization is equally important. Reviewing pricing, membership programs, treatment room utilization, and cost structure helps demonstrate efficiency. Branding and digital presence should also be refined early, as buyers heavily evaluate reputation, reviews, and online engagement. By addressing these elements proactively, owners position themselves to attract multiple offers—not just one—creating competition that drives up deal value.
Preparing Financials, KPIs, and Clinical Metrics for M&A Due Diligence
The most successful medspa exits begin with meticulous financial preparation. Buyers want clarity, predictability, and accuracy. This starts with well-organized financial statements—P&Ls, balance sheets, tax returns, and cash flow reports that align cleanly. Add-backs must be legitimate, well-documented, and easy to verify. Clean financials reduce friction during due diligence and increase buyer trust.
KPIs also play an essential role. Buyers analyze retention rates, revenue per provider, revenue per treatment room, patient frequency, membership penetration, and YOY growth. Practices that track KPIs consistently show stronger operational sophistication, which can boost valuation. Clinical metrics—such as complication rates, injector productivity, and device utilization—give buyers confidence in the medspa’s ability to deliver consistent outcomes.
Documenting SOPs, treatment protocols, and training processes is equally important. These elements prove that the business can operate smoothly after transition. A medspa with strong clinical governance shows significantly better long-term stability, which appeals to institutional buyers. When these metrics are well-organized, sellers move into negotiations from a position of strength.
How M&A Advisors Help MedSpas Navigate the 2025–2028 Deal Cycle
With preparation steps defined, we now move into the value an experienced M&A advisor brings through the complex stages outlined in the following H3 sections.
Working with a healthcare-focused M&A advisor is one of the most effective ways medspa owners can maximize their exit value. Advisors guide owners through each phase of the deal—valuation, preparation, buyer outreach, negotiations, and closing—ensuring sellers avoid the common pitfalls that reduce deal value. Their experience is especially important in the highly regulated aesthetic space, where compliance issues, supervisory requirements, and clinical risk can complicate transactions.
Advisors also understand buyer psychology. They know what private equity firms, MSOs, and strategic investors look for and how to position the business to appeal to their expectations. They prepare professional CIMs (Confidential Information Memorandums), analyze financials from a buyer’s perspective, and craft compelling narratives that highlight the practice’s strengths. During negotiations, they protect sellers from undervaluation by running competitive bidding processes that leverage multiple interested buyers.
In the 2025–2028 cycle, advisory firms are especially important because deal volume is high, and competition among buyers is fierce. Advisors help sellers structure earn-outs, equity rollovers, and transition agreements in ways that maximize long-term value. Their role becomes even more critical when evaluating offers that seem attractive on the surface but include hidden risks.
Avoiding Undervaluation and Common Negotiation Mistakes
Many medspa owners unintentionally undervalue their businesses because they enter negotiations without understanding buyer motivations or deal structures. Common mistakes include accepting the first offer, revealing weaknesses too early, misrepresenting financials, or negotiating without professional representation. Sellers also often underestimate the importance of timing—selling too early or too late can dramatically impact valuation.
One of the biggest errors is focusing solely on the purchase price while ignoring structure. Earn-outs, equity rollovers, seller financing, and working capital requirements can change the real value of the deal significantly. Experienced advisors help sellers analyze the full picture, ensuring they choose offers with the best long-term outcome—not just the highest initial dollar amount.
Another common mistake is failing to prepare staff for transition. If key team members appear uncertain or uncommitted, buyers may reduce the offer or walk away. Advisors help structure retention agreements and communication plans to prevent instability. They also help sellers avoid compliance missteps, which can lead to costly renegotiations. By preventing these mistakes, advisors protect the medspa’s value and ensure sellers exit at their peak.
Conclusion
The medspa industry is entering one of the most transformative M&A cycles in its history. Between 2025 and 2028, consolidation, technological advancement, and shifting consumer behavior will redefine what it means to operate—and sell—a successful medspa. Buyers are looking for operational excellence, clinical consistency, and scalable models that deliver predictable long-term returns. Sellers who take the time to prepare their financials, strengthen their teams, and optimize their service mix will be best positioned to capitalize on strong valuations and competitive buyer demand. With private equity, strategic healthcare groups, and consumer-health brands aggressively pursuing acquisitions, the next four years will offer unprecedented opportunities for well-prepared owners.
Ultimately, the key to maximizing exit value lies in readiness and professional guidance. Medspa owners who partner with experienced M&A advisors gain access to stronger deal structures, deeper buyer networks, and more favorable negotiations. As the market continues to evolve, preparation will separate those who capture premium valuations from those who get overlooked. The medspa landscape is shifting quickly—but with the right strategy, owners can leverage these changes for exceptional financial outcomes.
FAQs
1. What types of medspas will get the highest valuations from 2025–2028?
Medspas with strong recurring revenue, diversified service lines, multiple providers, clean financials, and strong brand presence generally command the highest valuations.
2. Are single-location medspas still attractive to buyers?
Yes—if they have strong profitability, scalable operations, and service mix diversity. However, multi-location practices typically receive more competitive offers.
3. How far in advance should a medspa owner prepare for a sale?
Ideally 12–24 months. This window allows time to optimize financials, strengthen operations, stabilize the team, and enhance compliance.
4. What is the biggest threat to medspa valuations?
Compliance issues, poor financial documentation, over-reliance on one injector, and underutilized devices are the top factors that decrease value.
5. How important are membership programs for valuation?
Extremely important. Memberships increase predictability, reduce churn, and create consistent cash flow—making medspas more appealing to investors.
6. Do private equity buyers require owners to stay on after the sale?
Often yes, for 6–24 months depending on the deal. Many owners also roll over equity to benefit from the platform’s future growth.
7. Can a medspa still sell if the owner is the primary injector?
Yes, but valuation is typically lower. Transition risk increases when the owner performs most clinical work. Building a provider team before selling boosts value.